Genmab
Focus: Genmab is a Netherlands-based biotechnology company specializing in monoclonal antibodies and antibody-drug conjugates for oncology. The company operates as a mid-cap biotech with a focused pipeline centered on hematologic and solid tumor malignancies.
Profile data last refreshed 7h ago · AI intelligence enriched 2w ago
Open Jobs
0
About Genmab
AI assessmentNot HiringNo open roles listed right now. Follow Genmab to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
2/9 — Limited
Company HealthSolid
Pipeline
Early-stage
50 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Key Products
GROWTH
Lead approved product with CD20-directed bispecific antibody mechanism; advancing in Phase 3 for DLBCL expansion and Phase 2 for additional NHL indications.
Products & Portfolio (1)
Help build intelligence for Genmab
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.